Here are five things to know:
1. The new appointment is effective immediately.
2. Mr. Lucier has been the interim CEO since April 1 after the previous CEO left his post due to compliance issues.
3. Mr. Lucier will maintain his role as chairman of the NuVasive board of directors.
4. He previously was the chairman and CEO of Life Technologies, a company he led for 11 years and transformed into a world-leading, global biotechnology firm with more than 50,000 products and nearly $4 billion in sales.
5. In his new role, Mr. Lucier is committed to scaling NuVasive’s business and more efficiently deploying resources for rapid growth outside of the United States. The company recently launched the Integrated Global Alignment platform.
“Since being appointed interim CEO, Greg has hit the ground running with an intense focus on driving NuVasive’s industry leadership,” said NuVasive Lead Independent Director of the Board Jack R. Blair. “As the board considered the needs of the company, we determined that this focus as well as Greg’s broad healthcare and leadership experience made him the right person to lead NuVasive forward. In addition to having a solid understanding of our strategy and business as a director, Greg brings a record of execution in areas that are also areas of strategic growth for NuVasive, including driving cutting-edge innovation, increased operational efficiencies and targeted expansion in key markets and geographies.”
More articles on orthopedic devices:
6 key trends in the North American joint reconstruction market
Orchid opens new India plant—5 things to know
8 trends in the China orthopedic instrument market
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
